$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth

$bpth Overview Financials Valuation SEC Filings Company Website

2012 Q3 Form 10-Q Financial Statement

#000114420412045860 Filed on August 14, 2012

Income Statement

Concept	2012 Q3	2012 Q2	2011 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$250.0K	$250.0K	$220.0K
YoY Change	-24.24%	-21.88%	-24.14%
% of Gross Profit
Research & Development	$550.0K	$190.0K	$580.0K
YoY Change	358.33%	35.71%	-4.92%
% of Gross Profit
Depreciation & Amortization	$50.00K	$50.00K	$50.00K
YoY Change	-16.67%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$840.0K	$787.8K	$800.0K
YoY Change	68.0%	69.87%	-12.09%
Operating Profit		-$787.8K
YoY Change		69.87%
Interest Expense	$0.00	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$0.00	-$56.00	$0.00
YoY Change		-105.49%	-100.0%
Pretax Income	-$840.0K	-$790.0K	-$800.0K
YoY Change	68.0%	71.74%	21.21%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$840.0K	-$787.8K	-$800.0K
YoY Change	68.0%	70.25%	21.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.897M	-$2.724M	-$2.759M
COMMON SHARES
Basic Shares Outstanding	58.87M shares	58.87M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q3	2012 Q2	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$330.0K	$160.0K	$950.0K
YoY Change	-66.33%	-86.89%	295.83%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$130.0K	$46.49K	$48.44K
YoY Change	160.0%	-7.02%	-69.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$460.0K	$504.4K	$1.154M
YoY Change	-55.77%	-60.28%	80.26%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles		$1.661M	$2.077M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.610M	$1.661M	$2.077M
YoY Change	-31.78%	-30.51%	-15.89%
TOTAL ASSETS
Total Short-Term Assets	$460.0K	$504.4K	$1.154M
Total Long-Term Assets	$1.610M	$1.661M	$2.077M
Total Assets	$2.070M	$2.165M	$3.231M
YoY Change	-39.12%	-40.84%	3.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$70.00K	$31.15K	$121.5K
YoY Change	75.0%	55.74%	35.04%
Accrued Expenses	$190.0K	$86.59K	$46.08K
YoY Change	18.75%	-56.71%	-71.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$270.0K	$243.0K	$316.1K
YoY Change	28.57%	10.47%	26.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$270.0K	$243.0K	$316.1K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$270.0K	$243.0K	$316.1K
YoY Change	28.57%	10.47%	26.45%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$58.87K	$58.33K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.800M	$1.922M	$2.915M
YoY Change
Total Liabilities & Shareholders Equity	$2.070M	$2.165M	$3.231M
YoY Change	-39.12%	-40.84%	3.89%

Cashflow Statement

Concept	2012 Q3	2012 Q2	2011 Q4
OPERATING ACTIVITIES
Net Income	-$840.0K	-$787.8K	-$800.0K
YoY Change	68.0%	70.25%	21.21%
Depreciation, Depletion And Amortization	$50.00K	$50.00K	$50.00K
YoY Change	-16.67%	0.0%	0.0%
Cash From Operating Activities	-$540.0K	-$630.0K	-$420.0K
YoY Change	54.29%	142.31%	180.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$110.0K
YoY Change	-100.0%	-100.0%	120.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$110.0K
YoY Change	-100.0%	-100.0%	120.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	710.0K	210.0K	500.0K
YoY Change	446.15%	-70.83%	47.06%
NET CHANGE
Cash From Operating Activities	-540.0K	-630.0K	-420.0K
Cash From Investing Activities	0.000	0.000	-110.0K
Cash From Financing Activities	710.0K	210.0K	500.0K
Net Change In Cash	170.0K	-420.0K	-30.00K
YoY Change	-170.83%	-193.33%	-121.43%
FREE CASH FLOW
Cash From Operating Activities	-$540.0K	-$630.0K	-$420.0K
Capital Expenditures	$0.00	$0.00	-$110.0K
Free Cash Flow	-$540.0K	-$630.0K	-$310.0K
YoY Change	63.64%	152.0%	210.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58868713	shares
CY2008Q2	bpth	Common Stock Additional Shares Issued CommonStockAdditionalSharesIssued	24	shares
CY2011Q2	us-gaap	Cash Cash	1221659
CY2012Q1	us-gaap	Other Inventory OtherInventory	21000
CY2012Q2	us-gaap	Other Assets Current OtherAssetsCurrent	46489
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	1922185
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58868713	shares
CY2012Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	168500
CY2012Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	22588
CY2012Q2	us-gaap	Liabilities Liabilities	243023
CY2012Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	31147
CY2012Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	10858812
CY2012Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q2	us-gaap	Assets Assets	2165208
CY2012Q2	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2500374
CY2012Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2165208
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58868713	shares
CY2012Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	50000
CY2012Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1660802
CY2012Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	86588
CY2012Q2	us-gaap	Other Inventory OtherInventory	295477
CY2012Q2	us-gaap	Cash Cash	162440
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	243023
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	58869
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	839572
CY2012Q2	us-gaap	Assets Current AssetsCurrent	504406
CY2011Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	39538
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2077414
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46082
CY2012Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	48439
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	2914974
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58325169	shares
CY2011Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	67971
CY2011Q4	us-gaap	Liabilities Liabilities	316131
CY2011Q4	us-gaap	Other Inventory OtherInventory	153000
CY2011Q4	us-gaap	Cash Cash	952252
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	316131
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	58325
CY2012Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	121540
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	791463
CY2011Q4	us-gaap	Assets Current AssetsCurrent	1153691
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12405395
CY2012Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12553628
CY2012Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent
CY2012Q2	bpth	Accrued Liabilities Related Parties Current AccruedLiabilitiesRelatedPartiesCurrent	52700
CY2012Q2	bpth	Common Stock Issuable Shares Issuable CommonStockIssuableSharesIssuable	550000	shares
CY2012Q2	bpth	Accrued Patent Expense Current AccruedPatentExpenseCurrent	25000
CY2010Q4	us-gaap	Grants Receivable GrantsReceivable	244479
CY2010Q4	us-gaap	Cash Cash	238565
CY2011Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	9548746
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2011Q4	us-gaap	Assets Assets	3231105
CY2011Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2868877
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3231105
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58325169	shares
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent
CY2011Q4	bpth	Accrued Liabilities Related Parties Current AccruedLiabilitiesRelatedPartiesCurrent	41000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1056505
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1396288
	us-gaap	Share Based Compensation ShareBasedCompensation	240664
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-26035
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-27846
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-375647
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37547
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1302
	us-gaap	Income Taxes Paid IncomeTaxesPaid
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	271
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	674812
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1396288
	us-gaap	Operating Expenses OperatingExpenses	1056505
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	983094
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-88400
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	104473
	us-gaap	Revenues Revenues
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	37547
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50524887	shares
	us-gaap	Net Income Loss NetIncomeLoss	-1055474
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1031
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-244479
	dei	Trading Symbol TradingSymbol	BPTH
	dei	Entity Registrant Name EntityRegistrantName	BIO-PATH HOLDINGS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2012-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001133818
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1310409
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	264709
	us-gaap	Share Based Compensation ShareBasedCompensation	34067
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-73108
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1950
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font: 10pt Times New Roman, Times, Serif"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The accompanying interim financial statements have been prepared with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principals. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of Bio-Path Holdings, Inc. (together with its subsidiary, the “Company”) as of and for the fiscal year ended December 31, 2011. The results of operations for the period ended June 30, 2012, are not necessarily indicative of the results for a full-year period.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6076744
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1029521
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	742
	us-gaap	Income Taxes Paid IncomeTaxesPaid
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	398
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	34067
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	483482
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>11. New Accounting Pronouncements</b></p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date.  If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</p> </div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="FONT: 10pt Times New Roman, Times, Serif"> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="WIDTH: 0.25in"><b>1.</b></td> <td><b>Organization and Business</b></td> </tr> </table> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path Holdings, Inc. (“Bio-Path” or the “Company”) is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates treat acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third Quarter 2010.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial will be tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data that will demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The current protocol for the trial requires evaluation of five doses of L-Grb-2 and enrollment of a sufficient number of patients in the study to achieve 18 to 30 evaluable patients. An evaluable patient is a patient who is able to complete the four-week treatment cycle. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.</p> <p style="TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt">  </p> <p style="TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> </p> <p style="TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the end of July 2011, the Company completed requirements for treating patients in the first cohort. The Company, its medical advisors and the Principal Investigator agreed that the data from the first cohort demonstrated that Liposomal Grb-2 was safe enough to proceed to the next cohort of the trial, which treated patients in the trial with a dose that was double the dose used in the first cohort. As a result of this review, the first cohort was closed and the second cohort was opened for recruiting patients into the clinical trial. In January of 2012, the Company completed requirements for treating patients in the second cohort. The Company, its medical advisors and the Principal Investigator agreed that the data from the second cohort demonstrated that Liposomal Grb-2 was safe enough to proceed to the third cohort of the trial, which is treating patients with a dose of 20 mg/m<sup>2</sup>, which is double the dose used in the second cohort. At the end of April, 2012, there were three evaluable patients in Cohort 3. As a result, a meeting of the Company’s medical advisory board was being scheduled to close the cohort and proceed to Cohort 4. Significantly, in the third cohort, all three patients completed the treatment cycle and were evaluable and, because of apparent stabilization from treatment with Bio-Path drug candidate Liposomal Grb-2, had received extended treatment cycles or were on hold for additional treatments pending increased supply of drug.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Based on the experience treating patients in Cohort 3, when all three patients benefited from treatment with Liposomal Grb-2 and were apparently stabilized, the assumption for drug requirements for Cohort 4 and beyond have increased significantly. Specifically, the assumption now is that all patients will benefit from treatment with the drug candidate Liposomal Grb-2 and be eligible to receive up to six months of treatments. In this regard, the Company increased the capacity of its drug supply chain, adding new suppliers for the Grb-2 drug substance and for the final drug product. Substantially increased supplies of the drug candidate Liposomal Grb-2 were delivered in July of 2012. As a result, Cohort 4 is now open and one patient has been enrolled and reportedly at least one patient from Cohort 3 is expected to start extended treatments.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Principal Investigator for the Phase I clinical trial, Dr. Jorge Cortes, is a leading expert in the treatment of CML, AML and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Hematology Society annual meeting in December of 2011. Results from the second cohort also demonstrated potential anti-leukemia benefits in treated patients. The Company is currently preparing an abstract updating the progress of Bio-Path’s clinical trial for presentation at the American Hematology Society annual meeting in December of 2012.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company expects that the patient testing requirements of the current protocol of the Phase I clinical trial will be completed during 2012. Since, at the Principal Investigator’s recommendation, some patients who are benefiting from the treatment are being placed on continuing therapy beyond the requirements of the clinical trial, additional expenses may be incurred as the Company is required to supply drug at no charge for the continuing treatment. Additional costs to completion of the current protocol for the Phase I clinical trial are estimated to range from $400,000 to $550,000. Bio-Path believes it has sufficient resources and access to additional resources to meet its obligations in this regard.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.</p> <p style="TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt">  </p> <p style="TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> </p> <p style="TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to immediately begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the end of January 2012, the Company’s Board of Directors held a strategic planning session. Among several topics was a discussion of Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology. The Company has commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $345,000 at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (50%). This amount represents one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $345,000, and cancel the license.</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path has become a publicly traded company (symbol OTCBB: BPTH) as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An important milestone was achieved for the Company in the second quarter, 2012 when Bio-Path’s common stock began trading on the quality-controlled OTCQX. OTCQX is the highest tier, premier trading platform for OTC companies and Bio-Path is very pleased to have qualified for the OTCQX given its high standards. The Company also announced that it had retained Roth Capital Partners to serve as the Company’s Designated Advisor for Disclosure (“DAD”) on OTCQX, responsible for providing guidance on OTCQX requirements. The OTCQX is a premier platform that distinguishes the best companies traded over-the-counter from the thousands of securities traded on the OTC Bulletin Board who are not required to meet any financial standards or undergo a qualitative review. Bio-Path’s commencement of trading on the OTCQX attests to the quality of the Company’s financial reporting and its technology. In addition, Roth Capital Partners is a firm with a strong life sciences research and investment banking practice and a focus on small-cap companies.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2012, Bio-Path had $162,440 in cash on hand. During the second quarter, 2012 the Company raised $235,000 through the sale of shares of its common stock to Lincoln Park Capital and to accredited investors through a private placement that the Company initiated at the beginning of the second quarter of 2012. The Company intends to raise up to $2 million through the sale of shares of common stock to accredited investors through the private placement and through the end of July, 2012 has raised approximately $1 million including amounts brought into the Company at the end of June, 2012. Bio-Path plans to begin raising significant amounts of additional development capital at anticipated higher share prices once there is demonstration of proof-of-concept of Bio-Path’s technology in human patients.</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.</p> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	264709
	us-gaap	Operating Expenses OperatingExpenses	1310409
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-789812
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	142477
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	96612
	us-gaap	Revenues Revenues
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58625066	shares
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-884710
	us-gaap	Investment Income Interest InvestmentIncomeInterest	77053
	us-gaap	Income Taxes Paid IncomeTaxesPaid
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	345000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	18500
	us-gaap	Net Income Loss NetIncomeLoss	-1310065
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	344
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11176410
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6703894
	us-gaap	Share Based Compensation ShareBasedCompensation	2984436
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	243023
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	46489
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3934
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6556848
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	244479
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	15000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7123894
	us-gaap	Operating Expenses OperatingExpenses	11176410
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	162440
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	295477
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	888075
	us-gaap	Revenues Revenues
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	420000
	us-gaap	Interest Paid InterestPaid	445
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	884710
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44693637	shares
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	690000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	318500
	us-gaap	Net Income Loss NetIncomeLoss	-10858812
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	317598
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	435000
CY2008Q2	bpth	Fair Value Of Common Stock Issued FairValueOfCommonStockIssued	180000
CY2011Q2	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	0
CY2011Q4	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	177440
CY2011Q4	bpth	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	1920000	shares
CY2011Q4	bpth	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	576000
CY2009	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
CY2011	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	345000
CY2011	bpth	Percentage Of Change In Depreciation Amortization Of Intangible Assets And Asset Impairment And Other Charges Operating PercentageOfChangeInDepreciationAmortizationOfIntangibleAssetsAndAssetImpairmentAndOtherChargesOperating	0.50	pure
CY2009Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-463768
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2011Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1111
CY2011Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	91
CY2011Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	324574
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	463768
CY2011Q2	us-gaap	Revenues Revenues
CY2011Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	51649169	shares
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-462748
CY2011Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1020
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-787782
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	213
CY2012Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	269
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	252168
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	787782
CY2012Q2	us-gaap	Revenues Revenues
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58868713	shares
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-787838
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-56
CY2012Q2	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	75000
CY2012Q2	bpth	Other Stock Based Compensation Expense OtherStockBasedCompensationExpense	0

Files In Submission

Name	View Source	Status
0001144204-12-045860-index-headers.html	Edgar Link	pending
0001144204-12-045860-index.html	Edgar Link	pending
0001144204-12-045860.txt	Edgar Link	pending
0001144204-12-045860-xbrl.zip	Edgar Link	pending
bpth-20120630.xml	Edgar Link	completed
bpth-20120630.xsd	Edgar Link	pending
bpth-20120630_cal.xml	Edgar Link	unprocessable
bpth-20120630_def.xml	Edgar Link	unprocessable
bpth-20120630_lab.xml	Edgar Link	unprocessable
bpth-20120630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v318602_10q.htm	Edgar Link	pending
v318602_ex31.htm	Edgar Link	pending
v318602_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth

2012 Q3 Form 10-Q Financial Statement

#000114420412045860 Filed on August 14, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPTH BIO-PATH HOLDINGS, INC. Stock $bpth

2012 Q3 Form 10-Q Financial Statement

#000114420412045860 Filed on August 14, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth